Acadia Pharma (ACAD) Q3 2026 Earnings Call Transcript
Acadia Pharma (ACAD) reported Q3 2026 total revenues of $342M, up 22% YoY. DAYBUE sales reached $140M, up 39% YoY, leading to raised 2026 guidance. NUPLAZID sales grew 12% YoY to $202M. The company extended DAYBUE patent protection to 2041 and plans a 2027 regulatory submission in Japan. Pipeline updates include remlifanserin and ACP-211, with peak sales potential of $11B.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise are likely to drive short‑term buying interest, while the mixed trial data for remlifanserin may temper longer‑term enthusiasm.
Market read
Acadia's strong quarter and raised guidance provide a clear catalyst for the stock, making the article highly relevant for traders.
What to watch
Potential regulatory delays in Japan could temper expectations.
Background
Acadia Pharma (NASDAQ:ACAD) focuses on treatments for rare neuro‑behavioral disorders. The Q3 2026 call disclosed financial results and pipeline updates.
Ticker impact
Acadia Pharma reported Q3 2026 revenue of $342M and raised its 2026 DAYBUE guidance, indicating strong growth.
likely upward pressure as investors price in higher future sales.
Revenue beat and guidance lift are fresh, material information that can move the stock immediately.
Market effects
Positive signal for biotech firms with rare‑disease pipelines.
U.S. biotech sector may see modest gains.
Limited to niche rare‑disease market.
Counterpoint
Some investors may question sustainability of growth given high R&D spend.
Key entities
- ExecutiveCatherine Owen Adams
Chief Financial Officer delivering earnings remarks.
- ExecutiveThomas Garner
Head of Commercial presenting sales performance.
